August 24, 2023

As oncology nurses, our personal biases can affect not only our own brains and cognitive functioning but also the mental health of those we interact with. We all have biases, or preconceived notions or ideas about particular people, groups, or circumstances. They frequently result from prior experiences, cultural and societal influences, and societal conditioning.

August 23, 2023

U.S. Representatives Diana DeGette (D-CO) and Debbie Wasserman Schultz (D-FL), along with more than 50 members of the U.S. Congress, wrote a letter in June 2023 calling on the U.S. Food and Drug Administration (FDA) to abide by a court-ordered deadline to review outstanding Premarket Tobacco Product Applications for e-cigarette products that remain on the market without approval. The call comes after FDA failed to meet the initial deadline of September 9, 2021, to complete its review of all pending e-cigarette applications.

August 23, 2023

More than twice as many of today’s cancer survivors say they’re experiencing functional limitations after their disease than those in 1999, according to study findings published in JAMA Oncology. The prevalence was also nearly twice as high as that reported in the general population, but it varied by diagnosis and was disproportionately higher among Black and Hispanic survivors.

August 22, 2023

In clinical trials, pirtobrutinib (Jaypirca™) was effective in restoring BTK inhibition in patients that experienced progression after previously receiving a covalent BTK inhibitor. Pirobrutinib became the first-available noncovalent (reversible) BTK inhibitor in January 2023 when the U.S. Food and Drug Administration granted it accelerated approval.

August 18, 2023

Join ONS member Ashley Barill, BSN, OCN®, nurse supervisor at WVU Medicine in Morgantown, WV, as she explains how she and her team train using mock code simulations in an outpatient infusion center in this video. Mock code simulations can help oncology nurses and other healthcare professionals prepare for emergencies, and Barill’s tips and resources are helpful tools when conducting those simulations. 

August 16, 2023

On August 14, 2023, the U.S. Food and Drug Administration approved melphalan (Hepzato™) for injection or hepatic delivery system (Hepzato Kit) containing melphalan as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.